Pfizer on Wednesday announced that final data on its coronavirus vaccine candidate showed it to be 95 percent effective, adding that the company would be applying for Federal Drug Administration (FDA) emergency authorization “within days.” 

Pfizer said that the vaccine candidate, developed with German company BioNTech, is 95 percent effective “against COVID-19 beginning 28 days after the first dose.” 

The company last week said that interim data revealed its vaccine to be 90 percent effective.

Join BJL on WhatsApp Status: Click here to Join BJL status for engagements, births, deals, levayos, events & more

Join BJL on WhatsApp Groups: Click here to Join an official BJL WhatsApp group for breaking news as it happens

It also said on Wednesday that it had the two months of safety data necessary to apply for an emergency use authorization from the FDA. 

“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic,” Dr. Albert Bourla, Pfizer Chairman and CEO, said in the company's statement. “With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world.”

Pfizer said that 170 people in its trial tested positive for COVID-19, with 162 of them receiving a placebo and 8 in the vaccine group.

The company added that the efficacy rate was consistent across age, gender, race and ethnicity groups, and that the effectiveness for adults older than 65, who are at higher risk of complications from COVID-19, was more than 95 percent.

Pfizer reported no major side effects or safety concerns connected with the vaccine candidate, although fatigue and headaches were reported in some test subjects following the second dose. Read more at The Hill